ID   S-TFE
AC   CVCL_R854
DR   RCB; RCB4699
DR   Wikidata; Q54951529
RX   PubMed=23760492;
CC   Population: Japanese.
CC   Doubling time: 98.2 hours (PubMed=23760492).
CC   Sequence variation: Gene fusion; HGNC; HGNC:13825; ASPSCR1 + HGNC; HGNC:11752; TFE3; Name(s)=ASPSCR1-TFE3, ASPL-TFE3; Note=In frame (PubMed=23760492).
CC   Derived from site: In situ; Kidney; UBERON=UBERON_0002113.
ST   Source(s): RCB=RCB4699
ST   Amelogenin: X
ST   CSF1PO: 10
ST   D13S317: 8,11
ST   D16S539: 11,12
ST   D5S818: 9,11
ST   D7S820: 12
ST   TH01: 6,7
ST   TPOX: 8
ST   vWA: 16,17
DI   NCIt; C27891; Renal cell carcinoma associated with Xp11.2 translocations/TFE3 gene fusions
DI   ORDO; Orphanet_319308; MiT family translocation renal cell carcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Female
AG   18Y
CA   Cancer cell line
DT   Created: 05-11-13; Last updated: 19-12-24; Version: 14
//
RX   PubMed=23760492; DOI=10.4161/cbt.24344; PMCID=PMC3813566;
RA   Hirobe M., Masumori N., Tanaka T., Kitamura H., Tsukamoto T.;
RT   "Establishment of an ASPL-TFE3 renal cell carcinoma cell line (S-TFE).";
RL   Cancer Biol. Ther. 14:502-510(2013).
//